欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2002, Vol. 7 ›› Issue (3): 224-230.

• 临床研究 • 上一篇    下一篇

西布曲明对肥胖伴糖脂代谢异常的治疗作用

王平芳, 杨雅, 廖二元, 颜湘, 张红, 何凌, 朱旭平   

  1. 中南大学湘雅二医院代谢研究所, 长沙 410011
  • 收稿日期:2002-02-19 修回日期:2002-03-13 发布日期:2020-12-01

Effect of sibutramine on the obesity with metabolic disorder of blood glu-cose and lipid

WANG Ping-Fang, YANG Ya, LIAO Er-Yuan, YAN Xiang, ZHANG Hong, HE Lin, ZHU Xue-Ping   

  1. Institute of Metabolism and Endocrinology, Xiang-Ya Medical College, Central South University, Changsha 410011
  • Received:2002-02-19 Revised:2002-03-13 Published:2020-12-01

摘要: 目的: 观察西布曲明(可秀) 对肥胖伴糖尿病、脂代谢异常患者的治疗作用。方法: 将体重指数大于 25 kg·m-2 无药物及相关疾病的影响者纳入观察对象, 测西布曲明干预前后的体重、腰围、腹围、臀围、血脂、空腹(FBS) 和餐后 2 h 的血糖(2PBS) 、胰岛素、糖化血红蛋白等指标的变化。结果: (1) 41 例肥胖患者经西布曲明干预后腹围、体脂含量、体脂重量治疗前后比较, 差异有显著性(P<0.01);(2) 其中18 例糖代谢异常患者空腹血糖(FBS) 、餐后 2 h 血糖(2PBS) 、腹围、体重治疗前后比较, 差异有显著性(P<0.01) 。 INS(胰岛素) 、HbAIC(糖化血红蛋白) 有改变, 但差异无显著性(P >0.05) 。 (3) TG(甘油三脂) 、CHO(总胆固醇) 、LDL(高密度脂蛋白) 、HDL(低密度脂蛋白), 差异有显著性(P<0.05) 结论西布曲明具有降低体重, 改善糖、脂代谢异常的作用。对于降低心血管疾病的危险因素高脂血症有显著疗效。

关键词: 西布曲明, 肥胖, 糖脂代谢异常

Abstract: AIM: To observe the effect of sibutramine on the obesity with metabolic disorder of blood glucose and lipid.METHODS: Subjects with BMI (body mass index) over 25 kg·m-2 were selected.The observedin-dexes included the weight, waist and hip measurements, abdomen measurement, blood lipid, blood glucose levels fasting and after a standard test meal (FBS and 2PBS), bloodinsulin, and glcosylated haemoglobine (HbAIC) level, before and after taking sibutramine.RESULTS: After taking sibutramine, it was significantly improved (P<0.01) in the abdomen measurement, lipid rate and lipid mass in the 41 patients with obesity.The FBS, 2PBS, weight, and abdominal measurement decreasedin 18 patients with metabolic disorder of blood glucose (P<0.01).The bloodinsulin and HbAIC had no significant changes, but triglycerides (TG), cholesterol (CHO), high-density lipoprotein (HDL), and low-density li-porotein (LDL) were improved.CONCLUSION: Sibu-tramine can decrease weight, improve the disorders of blood glucose and lipid, and decrease cardio-vascular dis-ease risk factors in the patients with metabolic disorder of blood gucose and lipid.

Key words: sibutramine, obesity, metabolic disor-ders of blood glucose and lipid

中图分类号: